Zacks Research Issues Optimistic Outlook for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for Edwards Lifesciences in a research report issued on Wednesday, December 11th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $0.62 per share for the quarter, up from their previous estimate of $0.61. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences’ FY2025 earnings at $2.43 EPS and Q1 2026 earnings at $0.67 EPS.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.59 earnings per share.

Other research analysts also recently issued research reports about the company. Barclays lifted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Evercore ISI reduced their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Finally, Truist Financial restated a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Stock Up 0.3 %

EW opened at $74.15 on Monday. The company has a market cap of $43.73 billion, a P/E ratio of 10.70, a P/E/G ratio of 3.63 and a beta of 1.12. The business’s 50-day moving average price is $69.72 and its 200-day moving average price is $73.71. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EW. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Peoples Bank KS purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC raised its stake in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,500 shares of company stock valued at $2,508,350 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.